Apellis Pharmaceuticals, Inc.
APLSDelisted May 14, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001492422
Apellis Pharmaceuticals, Inc. was delisted on May 14, 2026; its insiders filed their last Form 4 on May 14, 2026; 324 institutions reported holding it in 13F filings for Q1 2026, worth $5.56B in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:18 PM ET
Revenue flow, Q1 FY2026
Where the revenue went in Q1 FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one quarter, newest first.
| Line item | Q1 FY2026 | Q4 FY2025† | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024† | Q3 FY2024 | Q2 FY2024 |
|---|---|---|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 |
| Filing | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Reported | – | Jan 12, 2026 | – | – | – | Jan 13, 2025 | – | – |
| Revenue | $268.3M | $199.9M† | $458.6M | $178.5M | $166.8M | $212.5M† | $196.8M | $199.7M |
| Operating expenses | $241.8M | $251.1M† | $235.4M | $211.8M | $250.1M | $238.7M† | $244.1M | $229.1M |
| Research and development | $77.0M | $74.2M† | $68.2M | $67.0M | $86.4M | $76.4M† | $88.6M | $77.9M |
| Selling, general and administrative | $124.3M | $147.1M† | $142.7M | $131.1M | $129.3M | $121.5M† | $122.0M | $128.1M |
| Operating income | $26.5M | -$51.1M† | $223.2M | -$33.3M | -$83.3M | -$26.2M† | -$47.3M | -$29.4M |
| Income tax | $496.0K | $313.0K† | $602.0K | $466.0K | $341.0K | $286.0K† | $592.0K | $114.0K |
| Net income | $18.7M | -$59.0M† | $215.7M | -$42.2M | -$92.2M | -$36.4M† | -$57.4M | -$37.7M |
| EPS, basic | $0.15 | – | $1.71 | $-0.33 | $-0.74 | – | $-0.46 | $-0.30 |
| EPS, diluted | $0.15 | – | $1.67 | $-0.33 | $-0.74 | – | $-0.46 | $-0.30 |
| Weighted shares, basic | 127.7M | – | 126.4M | 126.0M | 125.5M | – | 124.2M | 123.9M |
| Weighted shares, diluted | 131.4M | – | 130.1M | 126.0M | 125.5M | – | 124.2M | 123.9M |
| Margins and growth | ||||||||
| Operating margin | 9.9% | -25.6% | 48.7% | -18.6% | -50.0% | -12.3% | -24.0% | -14.7% |
| Net margin | 7.0% | -29.5% | 47.0% | -23.6% | -55.3% | -17.1% | -29.2% | -18.9% |
| Revenue growth, year over year | +60.9% | −5.9% | +133.0% | −10.6% | −3.2% | +45.2% | +78.3% | +110.3% |
Balance sheet
Each column is one quarter, newest first.
| Line item | Q1 FY2026 | Q4 FY2025† | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024† | Q3 FY2024 | Q2 FY2024 |
|---|---|---|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 |
| Filing | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Reported | – | Jan 12, 2026 | – | – | – | Jan 13, 2025 | – | – |
| Cash and equivalents | $405.2M | $466.2M | $479.2M | $370.0M | $358.4M | $411.3M | $396.9M | $360.1M |
| Accounts receivable | $440.3M | $366.2M | $345.5M | $214.1M | $235.2M | $264.9M | $279.0M | $304.4M |
| Inventory | $131.4M | $142.6M | $122.8M | $121.0M | $82.5M | $81.4M | $121.1M | $152.8M |
| Total current assets | $1.03B | $1.01B | $990.7M | $755.6M | $727.7M | $789.0M | $833.9M | $860.0M |
| Property, plant and equipment | $1.42M | $1.71M | $1.93M | $2.12M | $2.51M | $2.95M | $3.38M | $3.84M |
| Total assets | $1.08B | $1.08B | $1.06B | $821.4M | $807.3M | $885.1M | $901.9M | $904.5M |
| Accounts payable | $49.0M | $56.8M | $38.6M | $54.2M | $55.3M | $38.6M | $42.7M | $38.3M |
| Total current liabilities | $283.4M | $323.6M | $279.5M | $200.7M | $178.4M | $185.5M | $191.3M | $169.2M |
| Total liabilities | $667.6M | $705.1M | $657.6M | $665.1M | $643.1M | $656.5M | $664.7M | $640.2M |
| Shareholders' equity | $414.9M | $370.1M | $401.2M | $156.3M | $164.2M | $228.5M | $237.1M | $264.3M |
Cash flow statement
Each column is one quarter, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | Q1 FY2026 | Q4 FY2025† | Q3 FY2025† | Q2 FY2025† | Q1 FY2025 | Q4 FY2024† | Q3 FY2024† | Q2 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 |
| Filing | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| Reported | – | Jan 12, 2026 | – | – | – | Jan 13, 2025 | – | – |
| Operating cash flow | -$61.0M | -$14.2M† | $108.5M† | $4.45M† | -$53.4M | $19.4M† | $34.1M† | -$8.34M† |
| Capital expenditures | – | $108.0K† | $148.0K† | $49.0K† | $8.00K | $20.0K† | $0† | $90.0K† |
| Free cash flow | – | -$14.3M | $108.3M | $4.40M | -$53.4M | $19.3M | $34.1M | -$8.43M |
| Stock-based compensation | $25.2M | $21.2M† | $28.2M† | $27.2M† | $27.4M | $26.3M† | $27.5M† | $30.0M† |
| Investing cash flow | – | -$108.0K† | -$148.0K† | -$49.0K† | -$8.00K | -$20.0K† | $0† | -$90.0K† |
| Financing cash flow | $64.0K | $1.26M† | $793.0K† | $6.56M† | $274.0K | -$4.00M† | $2.54M† | $42.5M† |
| Net change in cash | -$61.0M | -$12.8M† | $109.1M† | $11.6M† | -$52.8M | $14.4M† | $36.8M† | $34.4M† |
| Ratio | ||||||||
| Stock-based compensation, % of revenue | 9.4% | 10.6% | 6.1% | 15.2% | 16.4% | 12.4% | 14.0% | 15.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Apr 30, 2026 | 128.0M | +1.9% | SEC |
| Apr 21, 2026 | 128.0M | +1.9% | SEC |
| Feb 17, 2026 | 127.8M | +1.8% | SEC |
| Oct 23, 2025 | 126.5M | +1.7% | SEC |
| Jul 24, 2025 | 126.3M | +3.7% | SEC |
| Apr 30, 2025 | 125.7M | +3.6% | SEC |
| Feb 19, 2025 | 125.5M | +4.1% | SEC |
| Oct 29, 2024 | 124.4M | +5.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- Values marked † are derived: Q4 is the full year minus the first three quarters, single-quarter cash flows are year-to-date figures minus the previous year-to-date figures, and the Q4 balance sheet is the year-end balance sheet.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.